Foundry Partners LLC boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 2.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 90,967 shares of the medical research company’s stock after buying an additional 1,882 shares during the period. Foundry Partners LLC’s holdings in Charles River Laboratories International were worth $9,201,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Cambridge Advisors Inc. bought a new position in Charles River Laboratories International during the second quarter valued at about $202,000. Advisor Partners LLC bought a new position in Charles River Laboratories International during the second quarter valued at about $208,000. Campbell & CO Investment Adviser LLC bought a new position in Charles River Laboratories International during the second quarter valued at about $217,000. MAI Capital Management bought a new position in Charles River Laboratories International during the first quarter valued at about $224,000. Finally, Massmutual Trust Co. FSB ADV raised its position in Charles River Laboratories International by 5.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,739 shares of the medical research company’s stock valued at $246,000 after buying an additional 130 shares in the last quarter. 95.81% of the stock is owned by hedge funds and other institutional investors.

Shares of Charles River Laboratories International, Inc. (CRL) opened at 97.97 on Friday. The company has a 50-day moving average price of $99.80 and a 200-day moving average price of $91.67. The firm has a market capitalization of $4.66 billion, a price-to-earnings ratio of 25.82 and a beta of 1.02. Charles River Laboratories International, Inc. has a 12 month low of $67.20 and a 12 month high of $102.32.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The business had revenue of $469.13 million during the quarter, compared to analysts’ expectations of $458.25 million. During the same quarter in the prior year, the firm earned $1.20 EPS. The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. Equities analysts forecast that Charles River Laboratories International, Inc. will post $5.10 EPS for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, May 10th that authorizes the company to repurchase $150.00 million in shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

TRADEMARK VIOLATION NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/12/foundry-partners-llc-boosts-stake-in-charles-river-laboratories-international-inc-nysecrl.html.

Several research analysts have issued reports on the company. Jefferies Group LLC reiterated a “buy” rating and set a $121.00 price objective on shares of Charles River Laboratories International in a research note on Friday, June 30th. Zacks Investment Research lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Citigroup Inc. reiterated a “neutral” rating and set a $104.00 price objective (up from $91.00) on shares of Charles River Laboratories International in a research note on Wednesday, June 28th. Barclays PLC reiterated a “hold” rating and set a $102.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Finally, BidaskClub lowered Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. Charles River Laboratories International has an average rating of “Hold” and a consensus target price of $96.94.

In other news, insider Davide Molho sold 10,976 shares of the stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $92.84, for a total value of $1,019,011.84. Following the completion of the sale, the insider now owns 27,525 shares of the company’s stock, valued at $2,555,421. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director George Massaro sold 3,830 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $100.81, for a total value of $386,102.30. Following the completion of the sale, the director now directly owns 18,731 shares of the company’s stock, valued at approximately $1,888,272.11. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,369 shares of company stock valued at $7,846,412. Insiders own 2.20% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.